Brain cancer and changes in immune system
Key facts
- Where
- Budapest XII és Szeged, MagyarországSee the 2 sites
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old are you?
Where in Magyarország
- Orszagos Onkologiai IntezetBudapest XII, MagyarországTaking people
- University of SzegedSzeged, MagyarországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Orszagos Onkologiai Intezet
- Trial code
- EU 2024-512136-30-00
- Record updated
- 2024. június 28.
- Original description
An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusionRead full original descriptionShow less
An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
Inclusion: Not recurrent glioblastoma multiforme patients (either after opus or with no opus) before radiotherapy and temozolomide therapy. Recurrent patients who have already undergone other therapeutic intervention (surgery, radiotherapy and temozolomide therapy) and due to the recurrence of the disease, based on clinical experience, it is justified to start bevacizumab therapy. Known relapse patients who are already receiving bevacizumab therapy.
Exclusion: Unwillingness to sign the written Informed Consent Form. History of psychiatric diseases and treatment. Hypersensitivity to the active substance or to any of the excipients. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies. Participation in another clinical trial within 3 months prior to this study. Known drug or chronic alcohol abuse, drug addiction. Malignant disease other than GBM. Legal incapacity and/or other circumstances rendering the subject unable to understand the nature, scope and possible consequences of the study. Evidence of an uncooperative attitude. Vulnerable subject.